Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples